

SMI.LONDON

30 Euston Square, London

10 June 2026



www.smi.london

Advancing the Science of Soft Mist Inhalers

Welcome to SMI.London 2026, the fourth annual gathering of the world's most passionate community of soft mist inhaler enthusiasts, innovators, and pioneers.

I am absolutely thrilled to see you here with us today at 30 Euston Square. Whether you're a returning friend or stepping through these doors for the very first time, you belong here.

Come on in. Embrace it. The future of inhaled drug delivery is soft, is smart, and is here.

For this edition, we are turning our gaze toward the frontier. SMI.London 2026 is dedicated to **innovations from academia**: the discoveries being made right now in laboratories and clinical settings that are shaping the inhaled therapies of tomorrow. Expect to hear from key opinion leaders and trailblazers sharing the latest advances in device design, aerosol performance, and formulation science. The conversations today will be bold, rigorous, and exciting; as always.

Why does this matter? Because the numbers tell a remarkable story. Soft mist inhalers now represent nearly half of the

portable inhaler market. That is not a niche technology quietly finding its footing; that is a revolution underway. Recognised for their exceptional aerosol performance, deep-lung deposition, and low global warming potential, SMIs are the essential green inhaler, ahead of pMDIs and nebulisers by every meaningful measure. They are the platform of choice for early-phase clinical studies by paving the smoothest path to commercial product choice and market launch. With their remarkable compatibility with biologic therapies, they define the next generation of respiratory and systemic treatments.

Of course, no great conference is built on talks alone. It is built on the people in the room. If you haven't met your neighbour yet, now is the moment. Look around: sitting beside you are researchers, engineers, clinicians, and entrepreneurs from around the world, who share a fascination with the science of the perfect aerosol. Introduce yourself. Swap a business card. Start a collaboration. Some of the best ideas in this field have been born over cup of tea at SMI.London and today is no different. We have a planned speed networking session at the start of the day and many breaks. If you are shy or tongue-tied, we have

prepared icebreaker questions for you to test out.

I invite you to join our growing community on LinkedIn where you will find the largest online community in the world dedicated to Inhaled Drug Delivery: join the Inhaled Drug Delivery group ([linkedin.com/groups/69806](https://www.linkedin.com/groups/69806)) to stay connected, follow speaker updates, and keep the conversation going long after today.

After the event, the slides from all presentations will also be made available at www.smi.london, where you can revisit, share, and dive deeper into everything you've heard. Stay part of the dialogue — because the work we do here doesn't stop when we leave London.

A heartfelt thank you to our speakers, session chairs, exhibitors, and media partners, without whom none of this would be possible. Now, **let's make the future together.**

Have a brilliant day.


Philippe Rogueda
CBO of Merxin Ltd

#SMI.London26

#SoftMistInhalers

#InhaledDrugDelivery

#LetsBuildTheFutureTogether



Join the Conversation

Today is not just a conference — it is a moment worth sharing. If a talk sparks an idea, a discussion changes your perspective, or you simply want to mark the occasion, we encourage you to post about it. Tag your posts with **#SMILondon2026** and **#SoftMistInhalers** so the wider community can follow along, wherever they are in the world.

Connect with speakers, share highlights from the sessions, and introduce yourself to the **LinkedIn Inhaled Drug Delivery group** — the world's largest professional

community dedicated to this field, at **[linkedin.com/groups/69806](https://www.linkedin.com/groups/69806)**. Tag **#SMILondon26** in your posts and follow us to stay up to date with post-event content, slide releases, and news about SMI. London 2027.

Whether you share a graph, post a selfie with a new colleague, or distil a session into one killer takeaway — every post helps build the visibility of soft mist inhaler science and grows our community. Let the world know that this technology has a home, and that home is here.

Icebreaker Questions

Not sure how to strike up a conversation? Use these openers to break the ice, spark a debate, or simply find out who you're sitting next to. What if I don't know anyone? Perfect. That's exactly why you're here and so is everyone else.

pMDI, DPI, nebuliser or SMI. If you could only keep one inhaler type, which would it be and why? (Prepare to defend your answer.)

If SMIs could deliver *anything* (no regulations...), what would you spray?

Which country do you think will be the first to fully phase out pMDIs? (Bonus points if you give a year.)

Be honest: did you know what a soft mist inhaler was before you first encountered one professionally? (No judgement — most of us didn't.)

Conference hot take: which session are you most sceptical about going into today, and which are you most excited by?

What is the most useful thing you have ever learned from someone you met at a conference?

Are you more 'formulation-first' or 'device-first' in your thinking? (Or what talk do you wish someone had given?)

Now go and find out who you're sitting next to.

FAQs

What time does the day start and end?

Registration and refreshments open at 8:00. The first talk begins at 9:30. The day wraps up with a panel discussion at 16:30 and will close at 17:00.

Can I take Pictures of the slides?

There are no restriction on taking pictures, this is a public forum, just be mindful it is not annoying and speakers are not uncomfortable. Do respect copyrights.

Can I share content from the conference?

Yes, please do. Sharing helps build the community and spreads the word about SMI innovation.

Will the slides be available after the event?

Yes! Links to the speaker's slides will be available at www.smi.london after the event, subject to permission from each speaker. Keep an eye on the website and our LinkedIn group for the announcement.

Is there Wi-Fi?

Yes.

WiFi: **30EustonSquare**
No password required

Please ask a member of the team at registration if you have any trouble connecting.

Where can I find the exhibitors?

Exhibitors are set up in the networking area just outside the main conference room. Coffee breaks and lunch are the perfect time to visit, they are knowledgeable bunch.

I have a dietary requirement — is catering taken care of?

Full day catering is included in your registration. If you flagged a dietary requirement when you registered, it has been noted. If you didn't or you're not sure, please speak to a member of the team at registration and we will do our very best to help.

How do I get involved in SMI. London 2027?

We'd love to hear from you! Whether you are interested in speaking, exhibiting, sponsoring, or simply want to stay in the loop, drop us a line at info@smi.london or connect with us on LinkedIn.

I have a question that is not answered here — who do I ask?

Find a member of the team, we're the ones with the slightly harried but genuinely delighted expressions. You can also email info@smi.london and we will get back to you promptly.

Thank you to our Exhibitors:



8:00

Registration, refreshments and networking

Session 1:

Chaired by Peter Hirst, Head of BD, Merxin Ltd

9:30

Welcome to SMI.London 2026 - The SMI Year in Review

What is The Latest Gossip?

Dr. Philippe Rogueda,
CBO Merxin Ltd

9:45

Speed Networking Session

10:00

**Targeted Delivery
Enabled by Rayleigh
SMIs**

Hao-Ying Li, Researcher,
King's College London

Elucidate the essence of the formation of LNP-mRNAs.

Insights into the changes of LNP-mRNAs under shear stress (theoretically explain why VMN does not work).

Soft mists for the delivery of LNP-mRNAs to targeted regions in nasal cavity.

Soft mists for the delivery of LNP-mRNAs to the lungs.

Some corrigendum of concepts.

10:30

Coffee break, Exhibition & Networking

11:00

**PALM, A Tuneable
Low-Stress SMI
Platform**

Tuncay Alan,
Associate Professor,
Monash University

Nozzle-free oscillating microchannel technology generates low-velocity (<1 m/s), low-shear aerosols.

Tuneable droplet size and plume characteristics deliver precise aerosol performance, achieving 93% fine particle fraction (NGI).

The system delivers proteins and viscous formulations while preserving biological activity.

Adaptive dosing enables on-demand adjustment of output and droplet velocity, from low to high-throughput delivery.

Fully integrated handheld device combining microfluidics, actuation and electronic control, with cartridge-based delivery, designed for partner evaluation and scalable, low-cost manufacturing.

11:30

**Digital Twin
Evaluates SMI Lung
Dose**

Nicolas Schwenck,
Head of BD &
Partnerships,
Ebenbuild GmbH

Simulation of aerosol transport and regional deposition using CT-derived airway geometries and a physics-based whole-lung model.

Quantification of the local dose at the site of action across lung regions for pharmacopeial breathing assumptions and measured real-world breathing profiles.

Integration of in vitro aerosol characteristics from different aerosol-generating device classes: SMI, DPI and pMDI.

Device-class dependent differences in regional lung deposition identified across breathing patterns, enabling extension of the framework to virtual cohort studies for in silico evaluation of inhaled drug delivery.

12:00

Characterising SMI aerosol performance in vitro

Ben Forbes, Professor of Pharmaceutics, King's College London

Nasal Deposition.

Alberta Idealised Nasal Inlet.

Aerodynamic Particle Size Distribution.

Next Generation Impactor.

Effect of flow rate & Temperature.

12:15

Lunch, exhibition and networking

Session 2:

Chaired by Francesca Buttini, Associate Professor, University of Parma

13:30

How to Tune a Nasal SMI Product

Laleh Golshahi, PhD, Associate Professor, VCU & Founder & CEO, 3DInhale

Existing pre-clinical tools fail to capture combined device–technique–breathing effects.

Anatomical nasal casts enable controlled multi-parameter deposition evaluation.

Spray design and plume geometry dominate deposition over breathing.

Administration orientation drives regional coverage; generalized guidance is achievable.

Olfactory targeting likely requires device-specific, not generalized, strategies.

14:00

Improving ICU aerosol therapy with soft mist technology

Madeline Zhang, PhD
Researcher, University
of Amsterdam

On-demand absolute humidification using a soft mist nozzle decouples gas flow humidification from heating, while maintaining clinical safety thresholds.

Improved drug delivery efficiency by reducing undesired deposition in breathing circuits through partial evaporation of drug droplets, for both high-flow nasal cannula (HFNC) therapy and invasive mechanical ventilation (IMV).

Bench measurements translated to regional respiratory tract deposition using simulations, providing insights into effective dose in target regions.

Pulmonary diseases alter regional deposition, highlighting the potential need for adaptive aerosol therapy strategies.

14:30

An SMI delivery platform for siRNA therapeutics

Chantelle Ahlenstiel,
Professor, Kirby
Institute, UNSW
Sydney

Optimised LNP formulation for respiratory delivery of siRNA.

Targeting the nasopharynx for upper respiratory tract virus infections.

Advancing respiratory models with ALI-cultures and live virus challenge.

Safety and antiviral efficacy of siRNA-LNP in a SARS-CoV-2 mouse model.

Platform technology broadly applicable for respiratory disease.

15:00

Coffee break, Exhibition & Networking

Session 3:

Chaired by Ayca Pekoz, Professor, Istanbul University

15:30

Building The Future: Inhaled Therapies In Development

Darragh Murnane,
Professor of
Pharmaceutics,
University of
Hertfordshire & Royal
Society Industrial
Fellow, Merxin Ltd

A range of novel therapeutic modalities are emerging for respiratory delivery.

There are few examples of novel modalities with regulatory approvals to guide the pathway for development.

This talk will examine the types of therapeutic modalities currently in clinical trials and assess progression success through translational phases.

We will identify the range of therapeutic modalities which inhaler device specialists can expect to manage in the coming years.

16:00

The Ensifentrine Story: A Bifunctional Therapy For Respiratory Diseases

Prof. Clive P. Page OBE,
Professor of
Pharmacology, King's
College London

The need for new therapies for asthma and COPD.

Will discuss the discovery and development of ensifentrine.

First in class inhaled "bifunctional" drug combining anti-inflammatory and bronchodilator activity in a single molecule.

Positioning of ensifentrine in the treatment of COPD.

Future developments.

16:30

Panel Discussion & Final Remarks

17:00

Close of the day

**We are grateful for the support
of our Media Partners:**



Inhalation



Have a great day. See you next year?

**SMI.London 2026, an event planned and
coordinated by Merxin Ltd**

www.merxin.com


We Make Inhalers


**We will work with the speakers to share
the slides after the event, keep an eye on
the SMI.London website to access these
- follow the QR code below.**

**Wi-Fi : [30EustonSquare](#)
No password required**

**To follow conference news
and conversations please use:**







www.smi.london